Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Shifts Course With Alzheimer’s Drug Solanezumab

This article was originally published in The Pink Sheet Daily

Executive Summary

In another sign of uncertainty for Alzheimer’s disease drug development, Lilly shakes things up with announcement of design changes for Phase III trial for solanezumab.

You may also be interested in...



Lilly Executes Growth Strategy As New Products Drive Sales Gains

Eli Lilly & Co.'s first quarter earnings met analyst expectations with help from recently approved products, but greater growth in future years depends on a closely-watched Phase III Alzheimer's program.

Where Is The Patient Voice In Alzheimer's Disease Drug Development?

Companies focused on Alzheimer's R&D need to catch up on patient involvement, and earlier diagnosis may help, patient advocate suggests.

Standards For Early Alzheimer’s Drugs Adapted, Not Loosened, FDA’s Katz Says

A draft guidance for development of drugs to treat early Alzheimer’s disease does not loosen agency standards, FDA’s neurology products chief asserts. Rather, it is an attempt to establish criteria tailored to the population.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel